All News

The finding came from a systematic review and meta-analysis involving 32,298 patients enrolled across the 75 studies.

A personalized patient genetic index will be created to show the presence of bladder cancer as well as evaluate patient response to BCG immunotherapy,” says Marvin S. Hausman, MD.

"Based on the LEA and S1011 trials, it has become clear that patients do not benefit from an extended LND, and a standard bilateral pelvic LND is the standard of care," write Amir Soltani-Tehrani, MD, and Kamal S. Pohar, MD.

Health care practitioners utilizing telemedicine, regardless of the modality, must be cognizant of the many pitfalls of violating the rules regulating patient confidentiality as established by federal and state privacy laws.

The safety and efficacy of BXCL701 in combination with pembrolizumab is currently under investigation in a phase 2 trial.

"Our findings offer hope for those looking for ways to improve their quality of life after undergoing surgery, radiation, and other common therapies for prostate cancer, which can cause significant [adverse] effects," says Stacy Loeb, MD, MSc.

"As investigational therapies and devices make their way through the approval process and into practice, urologists should stay abreast of early clinical results and may look to publicly available information for costs and utilization trends," writes Robert A. Dowling, MD.

Independent health care practices rely on online ratings and reviews to attract new patients and establish themselves as leading, recognizable providers in their community.

"Not only does it impact trust in the information, but a lack of Black representation in prostate cancer content gave the impression that Black men are at lower risk for prostate cancer,” says Stacy Loeb, MD, MSc.

“Treatment based on visualization of 18F-flotufolastat–avid lesions may facilitate optimal targeting of recurrence sites and avoid futile salvage therapy,” said Przemyslaw Twardowski, MD.

“Our data showed a considerable gap in reporting patient-reported outcomes and in the quality of design and conduct of patient-reported outcomes-related trial endpoints," said Jad Chahoud, MD, MPH.

“With cancer patients living longer, understanding the adverse cardiac effects due to cancer treatments, such as androgen deprivation therapy (ADT), is critical," says Sagar Anil Patel, MD.

The conference explored the current and future use of PSMA-PET imaging and PSMA radioligand therapy to improve the clinical care of patients with prostate cancer.

PSMA uptake in the prostatic midline is often linked with urine stagnation in the prostatic urethra and can lead to misinterpretation on PSMA-PET/CT,” the authors wrote. “Using post-void MRIs may help reduce false positives.”

The panel recommended that baseline PSA testing be done in Black men between the ages of 40 to 45.

ZH9 is a proprietary bacterial immunotherapy administered to patients via a single-dose intravesical induction regimen.

“99mTc‐PSMA-SPECT/CT is useful in the primary diagnosis of prostate cancer,” the authors wrote.

"The data from the QUILT 3.032 Quality of Life study suggest that many patients not only have a durable response but also report no decline in physical function, which is very important for these patients,” says Karim Chamie, MD.

Prior authorizations for medical care will become quicker and easier, while saving money, according to the Centers for Medicare & Medicaid Services.

“The results suggest there is a clinically meaningful population of patients who can experience a long-term survival benefit from tivozanib over sorafenib,” said Kathryn E. Beckermann, MD, PhD.

“The more informed the patients are, the more likely they are to participate in decision making…Patient engagement in decisions reduces decisional regret and fosters patient satisfaction with treatment outcomes,” the researchers wrote.

"At MIU, we host many ancillary services, including complete ultrasound services, UroCuff, urodynamics, PTNS [percutaneous tibial nerve stimulation], full laboratory and pathology services, Xofigo [radium-223]," says Jason M. Hafron, MD.

“This data supports the clinical benefit of 177Lu-PSMA-617 in real-world clinical practice,” the researchers wrote in their poster conclusion.

"It adds to the evidence base that is building that shows that improving your fitness levels is a positive thing to do to reduce your risk of developing prostate cancer," says Kate A. Bolam Enarsson, PhD.

“Prostatic extracellular vesicles represent a promising biomarker with the potential for reduction of false positive rate in men with elevated PSA following mpMRI,” the authors wrote.

“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.

According to statistics provided by the AUA, 385 medical students and other applicants were matched across 148 urology residency training programs nationwide.

"This study identifies a new target for VTE prevention," writes Kate Gessner, MD, PhD, and Philip Abbosh, MD, PhD.